Compounds > carbapenems
Page last updated: 2024-09-04

carbapenems and rpx7009

carbapenems has been researched along with rpx7009 in 14 studies

Compound Research Comparison

Studies
(carbapenems)		Trials
(carbapenems)		Recent Studies (post-2010)
(carbapenems)		Studies
(rpx7009)		Trials
(rpx7009)		Recent Studies (post-2010) (rpx7009)
7,3551475,277100499

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (14.29)24.3611
2020's12 (85.71)2.80

Authors

AuthorsStudies
Abendroth, J; Atkins, K; Boyer, SH; Clifton, MC; Dudley, MN; Durso, S; Griffith, DC; Hecker, SJ; Hirst, GC; King, P; Lomovskaya, O; Loutit, JS; Morgan, EE; Potts, KT; Raymond, A; Reddy, KR; Sabet, M; Sun, D; Tarazi, Z; Totrov, M; Tsivkovski, R1
Ammerman, NC; Kaushik, A; Kreiswirth, BN; Lamichhane, G; Lee, J; Martins, O; Nuermberger, EL; Parrish, NM1
Ackley, R; Anderson, WE; Capraro, GA; Meredith, J; Minor, S; Polk, C; Roshdy, D1
Castanheira, M; Johnson, JR; Johnston, BD; Porter, SB; Thuras, P1
Carvalhaes, C; Castanheira, M; Deshpande, L; Shortridge, D1
Cressman, L; Lautenbach, E; Zhang, HL1
Birgy, A; Bonacorsi, S; Courroux, C; Danjean, M; Gits-Muselli, M; Hobson, CA; Monjault, A1
Bergman, Y; Cosgrove, SE; Jacobs, EB; Lee, JH; Lewis, S; Simner, PJ; Tamma, PD1
Carvalhaes, CG; Castanheira, M; Duncan, L; Kimbrough, JH; Mendes, RE; Sader, HS1
Gu, Y; Hu, D; Hu, M; Liang, R; Wang, D; Wang, M; Zhu, M1
Hsueh, PR; Ko, WC; Lee, YL1
Bouvier, M; Kerbol, A; Nordmann, P; Poirel, L; Raro, OHF; Sadek, M1
Barretti, P; Camargo, CH; Campos, KR; Cunha, MPV; de Souza, AR; Dos Santos, MB; Ferraro, PSP; Freire, MP; Sacchi, CT; Tiba-Casas, MR; Yamada, AY1
Gill, CM; Lee, SY; Nicolau, DP1

Other Studies

14 other study(ies) available for carbapenems and rpx7009

ArticleYear
Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
    Journal of medicinal chemistry, 2015, May-14, Volume: 58, Issue:9

    Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; Boronic Acids; Carbapenems; Crystallography, X-Ray; Drug Resistance, Bacterial; Drug Synergism; Gram-Negative Bacteria; Heterocyclic Compounds, 1-Ring; Mice; Microbial Sensitivity Tests; Models, Molecular; Rats; Stereoisomerism; Structure-Activity Relationship

2015
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:3

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactams; Boronic Acids; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous

2019
Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
    Antimicrobial agents and chemotherapy, 2020, 04-21, Volume: 64, Issue:5

    Topics: Aged; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Boronic Acids; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Ceftazidime; Cohort Studies; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae Infections; Female; Humans; Male; Meropenem; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Tract Infections

2020
Activity of meropenem/vaborbactam against international carbapenem-resistant Escherichia coli isolates in relation to clonal background, resistance genes, resistance to comparators and region.
    Journal of global antimicrobial resistance, 2021, Volume: 24

    Topics: Anti-Bacterial Agents; Asia; Boronic Acids; Carbapenems; Escherichia coli; Meropenem; Phylogeny

2021
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19).
    The Journal of antimicrobial chemotherapy, 2021, 09-15, Volume: 76, Issue:10

    Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Boronic Acids; Carbapenems; Humans; Meropenem; Microbial Sensitivity Tests; Pneumonia, Ventilator-Associated

2021
Real-world clinical outcomes of meropenem/vaborbactam for treatment of carbapenem-resistant Enterobacterales infections.
    Journal of global antimicrobial resistance, 2021, Volume: 27

    Topics: Adult; Anti-Bacterial Agents; Boronic Acids; Carbapenems; Humans; Meropenem; Retrospective Studies

2021
Evaluation of the inoculum effect of new antibiotics against carbapenem-resistant enterobacterales.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:11

    Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; Carbapenems; Cefiderocol; Humans; Imipenem; Meropenem; Tazobactam

2022
Comparing the activity of novel antibiotic agents against carbapenem-resistant Enterobacterales clinical isolates.
    Infection control and hospital epidemiology, 2023, Volume: 44, Issue:5

    Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefiderocol; Ceftazidime; Drug Combinations; Humans; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests

2023
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam activities against multidrug-resistant Enterobacterales from United States Medical Centers (2018-2022).
    Diagnostic microbiology and infectious disease, 2023, Volume: 106, Issue:2

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; United States

2023
In vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam alone or in combination with polymyxin B against carbapenem resistant Acinetobacter baumannii.
    The Journal of antibiotics, 2023, Volume: 76, Issue:9

    Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Meropenem; Microbial Sensitivity Tests; Polymyxin B

2023
In vitro activities of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam and other comparators against Pseudomonas aeruginosa isolates with discrepant resistance to carbapenems: Data from the Antimicrobial Testing Leadership and Surveil
    International journal of antimicrobial agents, 2023, Volume: 62, Issue:2

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azabicyclo Compounds; beta-Lactamases; Carbapenems; Ceftazidime; Cephalosporins; Doripenem; Humans; Imipenem; Leadership; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam

2023
Rapid meropenem/vaborbactam NP test for detecting susceptibility/resistance in Enterobacterales.
    The Journal of antimicrobial chemotherapy, 2023, 10-03, Volume: 78, Issue:10

    Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Drug Combinations; Gammaproteobacteria; Meropenem; Microbial Sensitivity Tests

2023
Genomic analysis and antimicrobial activity of β-lactam/β-lactamase inhibitors and other agents against KPC-producing Klebsiella pneumoniae clinical isolates from Brazilian hospitals.
    Scientific reports, 2023, 09-05, Volume: 13, Issue:1

    Topics: beta-Lactamase Inhibitors; Brazil; Carbapenems; Cefiderocol; Genomics; Klebsiella pneumoniae; Lactams; Meropenem

2023
Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    The Journal of antimicrobial chemotherapy, 2023, Dec-01, Volume: 78, Issue:12

    Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Drug Combinations; Imipenem; Lactams; Meropenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa

2023